-
公开(公告)号:US11066481B2
公开(公告)日:2021-07-20
申请号:US15746305
申请日:2016-07-22
发明人: Thomas Mikita , Lauren K. Ely , Huilan Gao , Yun Kim , Isaac J. Rondon , Tovo David , Shaun R. Coughlin
IPC分类号: C07K16/36
摘要: In one aspect, antibodies, or antigen-binding fragments thereof, that specifically bind to activated Factor XI (FXIa) are provided. Also provided are methods of obtaining such antibodies and nucleic acids encoding the same. In another aspect, compositions and therapeutic prevention of thrombotic diseases, disorders or conditions are provided. In another aspect, anti-idiotype antibodies that bind anti-FXIa antibodies of the disclosure, as well as compositions comprising the anti-idiotype antibodies, methods of obtaining the antibodies and nucleic acids encoding the same, are also provided.
-
公开(公告)号:US20210214414A1
公开(公告)日:2021-07-15
申请号:US17125903
申请日:2020-12-17
发明人: Stephen Berasi , Janet Elizabeth Buhlmann , Nathan Higginson-Scott , Michael Shamashkin , Matthew Russo , Stefano V. Gulla , Zong Sean Juo , Sreekumar R. Kodangattil , Weining Lu , Xueping Fan , David J. Salant
IPC分类号: C07K14/705 , C12N15/11 , C12N15/52 , C12N15/09 , C07K19/00 , C12N15/63 , C07H21/04 , A61K38/17 , A61P13/12
摘要: The invention provides recombinant Roundabout Receptor 2 (ROBO2) proteins designed to bind SLIT ligands and prevent their binding to ROBO2 cell surface receptors. Also provided are methods for use of these recombinant ROBO2 proteins.
-
公开(公告)号:US11059876B2
公开(公告)日:2021-07-13
申请号:US16286158
申请日:2019-02-26
申请人: Pfizer Inc.
发明人: Yik Andy Yeung , Reid Martin Renny Feldman , Ling Hon Matthew Chu , Javier Fernando Chaparro Riggers , Ivana Djuretic , Laura Lin , Lidia Mosyak
IPC分类号: C07K14/54 , A61K39/395 , A61K38/17 , A61K38/20 , A61K35/17 , C07K19/00 , A61P35/00 , C07K16/32 , C07K16/28 , C07K14/55 , C12N15/62 , A61K38/19 , A61K45/06
摘要: The present invention relates to human interleukin 15 (IL-15) variants that have therapeutic and diagnostic use, and methods for making thereof. The present invention also provides fusion proteins comprising a human IL-15 variant. Also provided are methods of stimulating or suppressing immune responses in a mammal, and methods of treating a disorder (e.g., cancer) using the IL-15 variants or the fusion protein of such IL-15 variants.
-
公开(公告)号:US20210163455A1
公开(公告)日:2021-06-03
申请号:US17171385
申请日:2021-02-09
申请人: Pfizer Inc.
发明人: Gary Erik Aspnes , Scott W. Bagley , John M. Curto , David James Edmonds , Mark E. Flanagan , Kentaro Futatsugi , David A. Griffith , Kim Huard , Yajing Lian , Chris Limberakis , Allyn T. Londregan , Alan M. Mathiowetz , David W. Piotrowski , Roger B. Ruggeri
IPC分类号: C07D405/12 , C07C53/06 , C07C53/10 , C07C215/40 , C07D405/14 , C07D413/14 , C07D471/04
摘要: Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
-
公开(公告)号:US20210145957A1
公开(公告)日:2021-05-20
申请号:US17161119
申请日:2021-01-28
申请人: Pfizer Inc.
发明人: Annaliesa Sybil Anderson , Amardeep Singh Bhupender Bhalla , Robert G.K. Donald , Jianxin Gu , Kathrin Ute Jansen , Rajesh Kumar Kainthan , Lakshmi Khandke , Jin-Hwan Kim , Paul Liberator , Avvari Krishna Prasad , Mark Edward Ruppen , Ingrid Lea Scully , Suddham Singh , Cindy Xudong Yang
摘要: The invention relates to immunogenic polysaccharide-protein conjugates comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B. streptococcus (GBS), and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the CP has a sialic acid level of greater than about 60%. The invention also relates to methods of making the conjugates and immunogenic compositions comprising the conjugates. The invention also relates to immunogenic compositions comprising polysaccharide-protein conjugates, wherein the conjugates comprise a CP from GBS serotype IV and at least one additional serotype. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.
-
公开(公告)号:US20210145817A1
公开(公告)日:2021-05-20
申请号:US17047428
申请日:2019-04-15
IPC分类号: A61K31/4545 , A61K9/16 , A61K9/00 , A61K9/48
摘要: Apixaban pharmaceutical formulation is provided. Also provided is a use of the apixaban formulation in treatment of a thromboembolic disorder.
-
公开(公告)号:US20210115159A1
公开(公告)日:2021-04-22
申请号:US16951003
申请日:2020-11-18
发明人: Pavel STROP , Magdalena Grazyna DORYWALSKA , Arvind RAJPAL , David SHELTON , Shu-Hui LIU , Jaume PONS , Russell DUSHIN
摘要: The present invention provides engineered polypeptide conjugates (e.g., antibody-drug-conjugates, toxin-(biocompatible polymer) conjugates, antibody-(biocompatible polymer) conjugates, and bispecific antibodies) comprising acyl donor glutamine-containing tags and amine donor agents. In one aspect, the invention provides an engineered Fc-containing polypeptide conjugate comprising the formula (Fc-containing polypeptide)-T-A, wherein T is an acyl donor glutamine-containing tag engineered at a specific site or comprises an endogenous glutamine made reactive by the Fc-containing polypeptide engineering, wherein A is an amine donor agent, and wherein the amine donor agent is site-specifically conjugated to the acyl donor glutamine-containing tag or the endogenous glutamine. The invention also provides methods of making engineered polypeptide conjugates using transglutaminase.
-
公开(公告)号:US10980815B2
公开(公告)日:2021-04-20
申请号:US16580667
申请日:2019-09-24
申请人: Pfizer Inc.
发明人: Andrew Fensome , Ariamala Gopalsamy , Brian S. Gerstenberger , Ivan Viktorovich Efremov , Zhao-Kui Wan , Betsy Pierce , Jean-Baptiste Telliez , John I. Trujillo , Liying Zhang , Li Xing , Eddine Saiah
IPC分类号: A61K31/506 , A61K31/55 , A61K45/06 , C07D401/14 , C07D403/14 , C07D405/14 , C07D487/08 , C07D519/00
摘要: A compound having the structure: or an acceptable salt thereof, wherein X is N or CR, where R is hydrogen, alkyl, etc.; A is selected from the group consisting of a bond, C═O, —SO2—, etc.; A′ is selected from the group consisting of a bond, C═O, etc.; Z is —(CH2)h— or a bond, etc.; R1 and R1′ are independently selected from the group consisting of hydrogen, alkyl, etc.; R2 is selected from hydrogen, alkyl, etc.; R3 is selected from the group consisting of hydrogen, and amino; R4 is monocyclic or bicyclic, etc.; R5 is independently selected from hydrogen, alkyl, etc.; h, j, k, m, n and q are integers as defined in the specification. Also provided are methods of treatment as Janus Kinase inhibitors and pharmaceutical compositions containing the compounds of the invention and combinations with other therapeutic agents.
-
公开(公告)号:US10968242B2
公开(公告)日:2021-04-06
申请号:US16702738
申请日:2019-12-04
申请人: PFIZER INC.
发明人: Martin James Wythes , Indrawan James McAlpine , Ryan Patman , Eugene Yuanjin Rui , Andreas Maderna , Mehran Jalaie , Ketan S. Gajiwala
IPC分类号: A61K31/7084 , A61K47/68 , A61P35/00 , C07H21/02 , C07H21/04 , C07F9/6574 , C07H19/213
摘要: Compounds of the general formula (I): or a pharmaceutically acceptable salt thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
-
公开(公告)号:US10966980B2
公开(公告)日:2021-04-06
申请号:US14822265
申请日:2015-08-10
申请人: Pfizer Inc.
发明人: Michael L. Vazquez , Neelu Kaila , Jamison B. Tuttle , Patrick Robert Verhoest , Matthew R. Reese , Karen J. Coffman , Tarek Samad , James M. Duerr , Simone Sciabola , Mihir D. Parikh
IPC分类号: C07D487/04 , C07D519/00 , C07D491/052 , C07D498/08 , C07D491/044 , A61K45/06 , A61K31/519 , A61K31/5377 , A61K31/5386
摘要: Described herein are pyrrolo{2,3-d}pyrimidine derivatives, their use as Janus Kinase (JAK) inhibitors, pharmaceutical compositions containing them, and therapeutic uses thereof.
-
-
-
-
-
-
-
-
-